- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07863024
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
A Phase 1/2 Study of REGN13089-M404-M2980, a MET-targeting Antibody-Drug Conjugate in Adult Participants With Previously Treated Advanced Solid Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
The study is focused on advanced cancers that have more of a protein called mesenchymal epithelial transition factor (MET) on the surface of their cells than usual. The study drug works by binding to MET on tumor cells and delivering chemotherapy directly into those cells. This may stop growth of the cancer cells and kill only the cancer cells and not the other normal tissues in your body. However, some of the chemotherapy may still affect the normal cells and side effects can still occur.
The study is looking at:
- What side effects the study drug might cause
- How well the study drug works
- How much of the study drug is in the blood at different times
- If the body reacts to the study drug, in a way that may cause the study drug to not work as well
- What is the best dose of the study drug for treating previously treated, advanced solid tumors
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Clinical Trials Administrator
- Numero di telefono: 844-734-6643
- Email: clinicaltrials@regeneron.com
Luoghi di studio
-
-
North Carolina
-
Huntersville, North Carolina, Stati Uniti, 28078
- Reclutamento
- Carolina BioOncology Institute
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
- Histologically confirmed cancer (non-small cell lung cancer (epidermal growth factor receptor mutant type or epidermal growth factor receptor mutant type), colorectal cancer, gastric/gastroesophageal junction cancer, uveal melanoma, papillary renal cell carcinoma, or clear cell renal cell carcinoma) that is at an advanced stage as described in the protocol
- Participants must not be candidates for curative surgery or radiation
- Participants are required to have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment refractory disease, or intolerance of the therapy as described in the protocol
- Willing to provide tumor tissue; archival or fresh tumor tissue will be accepted as described in the protocol
- At least 1 lesion that is measurable by RECIST 1.1. Tumor lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions after radiation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ and bone marrow function as described in the protocol
Key Exclusion Criteria:
- Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device as described in the protocol
- Has received radiation therapy within the 28 days prior to first administration of study intervention. Palliative stereotactic radiation therapy without a thoracic or abdominal field is allowed with a washout period of 14 days from first administration of study intervention.
- Has undergone major surgery within the 14 days prior to first administration of study intervention
- Has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities resulting from prior therapy as described in the protocol
- Has a history of interstitial lung disease (eg, idiopathic pulmonary fibrosis, etc) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management or has imaging consistent with these diseases during the screening period. A history of radiation pneumonitis is permitted as long as pneumonitis resolved ≥6 months prior to enrollment.
- Has received prior treatment with an antibody-drug conjugate (ADC) that includes a topoisomerase payload
- Known active or untreated brain metastases or spinal cord compression. Participants are eligible if central nervous system (CNS) metastases are adequately treated, and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment.
Note: Other protocol defined inclusion/ exclusion criteria apply
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Parte 1: aumento della dose
|
Administered per the protocol |
|
Sperimentale: Parte 2: espansione della dose
|
Administered per the protocol |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Occurrence of dose-limiting toxicities (DLTs)
Lasso di tempo: Up to 21 days
|
Part 1 (Dose Escalation) |
Up to 21 days
|
|
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Lasso di tempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Occurrence of Serious Adverse Events (SAEs)
Lasso di tempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Occurrence of adverse event of special interests (AESIs)
Lasso di tempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Objective response (OR) (investigator assessed) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Lasso di tempo: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective response (investigator assessed) per RECIST 1.1
Lasso di tempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Concentrations of ADC
Lasso di tempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Concentrations of total antibody
Lasso di tempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Concentrations of payload (ProDXd and DXd)
Lasso di tempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Occurrence of Anti-Drug Antibodies (ADA) against REGN13089-M404-M2980
Lasso di tempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Magnitude of ADA against REGN13089-M404-M2980
Lasso di tempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Duration of response per RECIST 1.1
Lasso di tempo: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Time to response per RECIST 1.1
Lasso di tempo: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Progression-free survival per RECIST 1.1
Lasso di tempo: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Overall survival
Lasso di tempo: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Occurrence of TEAEs considered clinically significant
Lasso di tempo: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Laboratory abnormalities considered clinically significant
Lasso di tempo: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Clinical Trial Management, Regeneron Pharmaceuticals
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- NSCLC
- INCONTRATO
- Cancro colorettale
- Tumore gastrico
- Carcinoma polmonare non a piccole cellule
- Cancro avanzato
- Metastatico
- Non resecabile
- Cancro della giunzione gastroesofagea
- Tumore solido metastatico
- ADC
- Primo tra gli umani
- Melanoma uveale
- Coniugato anticorpo-farmaco
- Carcinoma a cellule renali a cellule chiare
- FIH
- Malignità solida avanzata
- Carcinoma papillare a cellule renali
- METxMET antibody-drug conjugate
- Solid neoplasm
- Unresectable solid tumor
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Processi patologici
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie intestinali
- Malattie delle vie respiratorie
- Neoplasie per tipo istologico
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Malattie dello stomaco
- Neoplasie intestinali
- Malattie del retto
- Malattie polmonari
- Malattie degli occhi
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Malattie del colon
- Processi neoplastici
- Neoplasie polmonari
- Neoplasie urologiche
- Carcinoma
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Neoplasie renali
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Tumori neuroendocrini
- Nevi e melanomi
- Neoplasie oculari
- Malattie uveali
- Melanoma
- Condizioni patologiche, segni e sintomi
- Neoplasie uveali
- Neoplasie allo stomaco
- Neoplasie colorettali
- Metastasi neoplastica
- Carcinoma, cellule renali
- Carcinoma, polmone non a piccole cellule
- Melanoma uveale
Altri numeri di identificazione dello studio
- R13089-ONC-25128
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Periodo di condivisione IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Criteri di accesso alla condivisione IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- CODICE_ANALITICO
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .